Streptococcus pneumoniae and Pseudomonas aeruginosa pneumonia induce distinct host responses

Objective:Pathogens that cause pneumonia may be treated in a targeted fashion by antibiotics, but if this therapy fails, then treatment involves only nonspecific supportive measures, independent of the inciting infection. The purpose of this study was to determine whether host response is similar after disparate infections with similar mortalities. Design:Prospective, randomized controlled study. Setting:Animal laboratory in a university medical center. Interventions:Pneumonia was induced in FVB/N mice by either Streptococcus pneumoniae or two different concentrations of Pseudomonas aeruginosa. Plasma and bronchoalveolar lavage fluid from septic animals was assayed by a microarray immunoassay measuring 18 inflammatory mediators at multiple time points. Measurements and Main Results:The host response was dependent on the causative organism as well as kinetics of mortality, but the pro-inflammatory and anti-inflammatory responses were independent of inoculum concentration or degree of bacteremia. Pneumonia caused by different concentrations of the same bacteria, Pseudomonas aeruginosa, also yielded distinct inflammatory responses; however, inflammatory mediator expression did not directly track the severity of infection. For all infections, the host response was compartmentalized, with markedly different concentrations of inflammatory mediators in the systemic circulation and the lungs. Hierarchical clustering analysis resulted in the identification of five distinct clusters of the host response to bacterial infection. Principal components analysis correlated pulmonary macrophage inflammatory peptide-2 and interleukin-10 with progression of infection, whereas elevated plasma tumor necrosis factor sr2 and macrophage chemotactic peptide-1 were indicative of fulminant disease with >90% mortality within 48 hrs. Conclusions:Septic mice have distinct local and systemic responses to Streptococcus pneumoniae and Pseudomonas aeruginosa pneumonia. Targeting specific host inflammatory responses induced by distinct bacterial infections could represent a potential therapeutic approach in the treatment of sepsis.

[1]  Ian W. Dawes,et al.  Gene-expression profiling of peripheral blood mononuclear cells in sepsis* , 2009, Critical care medicine.

[2]  D. Glidden,et al.  Increased mortality of ventilated patients with endotracheal Pseudomonas aeruginosa without clinical signs of infection* , 2008, Critical care medicine.

[3]  古谷 良輔,et al.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. , 2008, American journal of respiratory and critical care medicine.

[4]  D. Fry.  The generic septic response. , 2008, Critical care medicine.

[5]  Stephen J. Huang,et al.  Gene-expression profiling of Gram-positive and Gram-negative sepsis in critically ill patients* , 2008, Critical care medicine.

[6]  Weixiong Zhang,et al.  Plasticity of the Systemic Inflammatory Response to Acute Infection during Critical Illness: Development of the Riboleukogram , 2008, PloS one.

[7]  Steven B. Johnson,et al.  Gene Expression Profiles Differentiate Between Sterile SIRS and Early Sepsis , 2007, Annals of surgery.

[8]  C. Coopersmith,et al.  Epithelial apoptosis in mechanistically distinct methods of injury in the murine small intestine. , 2007, Histology and histopathology.

[9]  J. Banchereau,et al.  Gene expression patterns in blood leukocytes discriminate patients with acute infections. , 2007, Blood.

[10]  J. Pugin,et al.  Contribution of Toll-like receptors to the innate immune response to Gram-negative and Gram-positive bacteria. , 2007, Blood.

[11]  D. Foell,et al.  S100 proteins expressed in phagocytes: a novel group of damage‐associated molecular pattern molecules , 2007, Journal of leukocyte biology.

[12]  D. Rittirsch,et al.  The disconnect between animal models of sepsis and human sepsis , 2007, Journal of leukocyte biology.

[13]  F. Bozza,et al.  INCREASED SUSCEPTIBILITY TO SEPTIC AND ENDOTOXIC SHOCK IN MONOCYTE CHEMOATTRACTANT PROTEIN 1/CC CHEMOKINE LIGAND 2-DEFICIENT MICE CORRELATES WITH REDUCED INTERLEUKIN 10 AND ENHANCED MACROPHAGE MIGRATION INHIBITORY FACTOR PRODUCTION , 2006, Shock.

[14]  A. Prince,et al.  Cell signaling underlying the pathophysiology of pneumonia. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[15]  John D. Storey,et al.  A network-based analysis of systemic inflammation in humans , 2005, Nature.

[16]  R. Nau,et al.  Minimizing the release of proinflammatory and toxic bacterial products within the host: a promising approach to improve outcome in life-threatening infections. , 2005, FEMS immunology and medical microbiology.

[17]  D. Hess,et al.  Impact of the indigenous flora in animal models of shock and sepsis. , 2004, Shock.

[18]  Steven B. Johnson,et al.  Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels* , 2004, Critical care medicine.

[19]  B. Beutler,et al.  The interface between innate and adaptive immunity , 2004, Nature Immunology.

[20]  Jeremy J. W. Chen,et al.  Differential gene expression in gram-negative and gram-positive sepsis. , 2004, American journal of respiratory and critical care medicine.

[21]  T. van der Poll,et al.  Role ofToll-Like Receptor 4 in Gram-Positive and Gram-Negative Pneumonia inMice , 2004, Infection and Immunity.

[22]  A. Chinnaiyan,et al.  Development of a Sensitive Microarray Immunoassay and Comparison With Standard Enzyme-Linked Immunoassay for Cytokine Analysis , 2004, Shock.

[23]  Nnis System.  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. , 2003, American journal of infection control.

[24]  H. Baker,et al.  Molecular Characterization of the Acute Inflammatory Response to Infections with Gram-Negative versus Gram-Positive Bacteria , 2003, Infection and Immunity.

[25]  C. Natanson,et al.  Protection with Antibody to Tumor Necrosis Factor Differs with Similarly Lethal Escherichia coli versus Staphylococcus aureus Pneumonia in Rats , 2003, Anesthesiology.

[26]  C. Coopersmith,et al.  Sepsis from Pseudomonas aeruginosa pneumonia decreases intestinal proliferation and induces gut epithelial cell cycle arrest. , 2003, Critical care medicine.

[27]  C. Coopersmith,et al.  Antibiotics Improve Survival and Alter the Inflammatory Profile in a Murine Model of Sepsis From Pseudomonas aeruginosa Pneumonia , 2003, Shock.

[28]  R. Hotchkiss,et al.  The pathophysiology and treatment of sepsis. , 2003, The New England journal of medicine.

[29]  Charles Natanson,et al.  Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. , 2002, American journal of respiratory and critical care medicine.

[30]  C. Coopersmith,et al.  Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis. , 2002, JAMA.

[31]  J. Vincent,et al.  Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study , 2001, Critical care medicine.

[32]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[33]  P. Andrew,et al.  Role of Genetic Resistance in Invasive Pneumococcal Infection: Identification and Study of Susceptibility and Resistance in Inbred Mouse Strains , 2001, Infection and Immunity.

[34]  Nnis System,et al.  National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990-May 1999, issued June 1999. A report from the NNIS System. , 1999, American journal of infection control.

[35]  L. Magnotti,et al.  Gut-derived mesenteric lymph but not portal blood increases endothelial cell permeability and promotes lung injury after hemorrhagic shock. , 1998, Annals of surgery.

[36]  J. E. Carceller.  American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis , 1992, Critical care medicine.

[37]  R. Schreiber,et al.  Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. , 1989, Journal of immunology.

[38]  R. L. Fulton,et al.  Multiple system organ failure. The role of uncontrolled infection. , 1980, Archives of surgery.

[39]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[40]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. , 2009, Chest.

[41]  C. Deutschman,et al.  Physiology and metabolism in isolated viral septicemia. Further evidence of an organism-independent, host-dependent response. , 1987, Archives of surgery.